Differential mitogenic signaling in insulin receptor-deficient fetal pancreatic β-cells by Guillen, C. et al.
1Differential mitogenic signaling in insulin receptor-deficient fetal pancreatic beta cells. 
Abbreviated title: Mitogenic signaling in fetal pancreatic beta cells 
C. Guillen1, P. Navarro1, M. Robledo, A.M. Valverde and M. Benito# 
Institute of  Biochemistry/Department of Biochemistry and Molecular Biology, Joint Center 
CSIC/UCM, School of Pharmacy, Complutense University, 28040-Madrid, Spain. 
#Corresponding and reprint requests author: Instituto de Bioquímica/Departamento de 
Bioquímica y Biología Molecular, Facultad de Farmacia, Ciudad Universitaria, 28040 
Madrid, Spain. Phone: 34-91-3941777; Fax: 34-91-3941779. E- mail: benito@farm.ucm.es
1: Equal contributors to this manuscript. 
Keywords: fetal pancreatic beta cells, insulin receptor, insulin signaling, glucose signaling,  
mitogenesis.  
This work was supported by grants SAF 2001/1302 and SAF 2002/00863 from Ministerio 
de Educación y Ciencia, Spain. We also recognize the support of “Red de Grupos de 
Diabetes Mellitus” (G03/212), Instituto de Salud Carlos III, Ministerio de Sanidad y 
Consumo, Spain.
 Endocrinology. First published January 5, 2006 as doi:10.1210/en.2005-0831
Copyright (C) 2006 by The Endocrine Society 
2Abstract Purpose of the investigation: Insulin receptor (IR) may play an essential role in 
the development of beta cell mass in the mouse pancreas. To further define the function of 
this signaling system in beta cell development, we have generated IR-deficient beta cell 
lines. Methods: Fetal pancreata were dissected from mice harboring a floxed allele of the 
insulin receptor (IRLoxP) and used to isolate islets. These islets were infected with a 
retrovirus to express SV40 large T antigen, a strategy for establishing beta cell lines (β-
IRLoxP). Subsequently, these cells were infected with adenovirus encoding cre 
recombinase to delete insulin receptor (β-IR-/-). Results: Beta cells expressed insulin and 
Pdx-1 mRNA in response to glucose. In β-IRLoxP beta cells, p44/p42 MAPK and PI 3 
kinase pathways, mTOR and p70S6K phosphorylation and β-cell proliferation were 
stimulated in response to insulin. Wortmannin or PD98059 had no effect on insulin-
mediated mTOR/p70S6K signaling and the corresponding mitogenic response. However, 
the presence of both inhibitors totally impaired these signaling pathways and mitogenesis 
in response to insulin. Rapamycin completely blocked insulin-activated mTOR/p70S6K 
signaling and mitogenesis. Interestingly, in ß-IR-/- beta cells, glucose failed to stimulate PI 
3 kinase activity, but induced p44/p42 MAPKs and mTOR/p70S6K phosphorylation and 
beta-cell mitogenesis. PD98059, but not wortmannin, inhibited glucose-induced 
mTOR/p70S6K signaling and mitogenesis in those cells. Finally, rapamycin blocked 
glucose-mediated mitogenesis of β-IR-/- cells. Conclusions: Independently of glucose, 
insulin can mediate mitogenesis in fetal pancreatic beta-cell lines. However, in the absence 
of the insulin receptor, glucose induces beta-cell mitogenesis. 
3Abbreviations: BSA, bovine serum albumin; FBS, fetal bovine serum; IRS, insulin receptor 
substrate; IR, insulin receptor; IGF-I, insulin like growth factor; IGF-IR, insulin like growth 
factor receptor; PI, phosphatidylinositol; PKC, protein kinase C; PAGE, polyacrylamide gel 
electrophoresis; PBS, phosphate-buffered saline; Tyr(P), phosphotyrosine.  
4Introduction 
Type 2 diabetes mellitus (NIDDM) is a complex metabolic disease with 
environmental and genetic origins which affects over 5% of the population in Western 
societies. The pathogenesis of type 2 diabetes involves abnormalities in both peripheral 
insulin action and insulin secretion by pancreatic beta-cells (1). Transgenic technology has 
yielded various animal models of type 2 diabetes and these have advanced significantly the 
analysis of insulin signaling molecules implicated in the regulation of glucose homeostasis 
(2). Recently, conditional knockout mice have been generated to define the specific roles 
of the insulin receptor (IR) and the insulin like growth factor I (IGF-IR) in pancreatic beta 
cell development (3, 4). Beta-cell specific insulin receptor deficiency (BIRKO mice) 
causes defective insulin secretion, which leads to progressive glucose intolerance and 
hyperglycemia. This diabetic phenotype reflects an impairment of acute insulin secretion in 
response to glucose in fed mice, which is characteristic of patients with type-II diabetes 
(3). Total pancreas insulin content is severely reduced in adult BIRKO mice as compared 
with controls. Moreover, gene expression analysis has revealed a significant reduction of 
GLUT 2 and glucokinase in both diabetic and non-diabetic BIRKO mice. However, 
reductions of beta-cell mass, islet number and insulin secretion are more pronounced in 
diabetic than in non-diabetic mutant mice (5). Taken together, these data implicate a direct 
role for the insulin receptor in the beta-cell growth and suggest that this receptor may also 
modulate the glucose sensing machinery required for normal insulin secretion.  
Interestingly, the beta-cell specific deletion of the IGF-IR creates a phenotype 
similar to BIRKO mice. These transgenic animals display a defect in glucose-stimulated 
insulin secretion due to reduced expression of GLUT 2 and glucokinase, resulting in 
impaired glucose tolerance. However, no effect on beta-cell mass and islet number was 
noted in mutant mice as compared with controls (4). These data suggest that IGF-IR is not 
5essential for beta-cell growth and development, but participates in the mechanisms of 
glucose-stimulated insulin secretion of pancreatic beta cells. 
Although still controversial, it appears that pancreatic beta cells arise from two 
main sources. New islets can be formed via budding from the pancreatic ductal epithelium 
(neogenesis) or through the proliferation of existing islets (6, 7). Whereas neogenesis 
occurs during fetal development (8) and the regeneration of adult pancreas (9), pancreatic 
beta-cell proliferation has been observed in the late fetal stages and also in normal adult 
pancreatic islet cells (6, 8). Of the signals involved in triggering beta-cell mitogenesis, 
IGF-I is one of the best characterized. However, IGF-I induced beta-cell proliferation 
appears to depend on glucose, which alone is classic beta-cell mitogen (10-12). Thus, 
glucose at low concentrations (5mM) activates p42/p44 MAPK and p70S6K by differential 
mechanisms in insulinoma cells; whereas glucose stimulates p42/p44 MAPK in a Ca2+-
dependent manner, p70S6K activation was achieved in an ATP-dependent manner (13). At 
high concentrations (16.5 mM), glucose induced insulin secretion in islets and lines of 
insulinomas but this effect required the expression of the transcriptional factor IPF-1/PDX-
1. In fact, mutation of the Pdx-1 transactivation domain impaired insulin secretion in 
response to 16.7 mM glucose in INS-1 beta-cells. Interestingly, the expression of PDX-1 in 
INS-1 beta-cells is four-fold higher than in isolated islets; consequently, insulin secretion 
by these insulinoma-derived beta cells is highly responsive to glucose. However, it is 
uncertain whether the effect of glucose on insulinoma proliferation might reflect an 
underlying defect in insulin secretion. To address this important issue, we have generated 
fetal pancreatic beta cells without the insulin receptor. These cell lines have allowed us to 
examine the role of insulin in beta-cell proliferation and conversely, to analyze the glucose 
signaling component of beta-cell mitogenesis in the absence of insulin receptor signaling.  
6Materials and methods 
Materials 
      Fetal calf serum and culture media were obtained from Gibco Inc. (Gaithersbury, MD). 
Insulin, crystal violet (#0775) and anti-mouse IgG-Agarose were from Sigma Chemical 
CO. (St. Louis, MO). Protein A-agarose was from Roche Molecular Biochemicals 
(Mannheim, Germany). The anti-TyrP (Py20) (sc-508), proliferating cell nuclear antigen 
(PCNA #sc-56) and anti-insulin (sc-9168) antibodies were purchased from Santa Cruz 
(Santa Cruz Biotechnology, Palo Alto, CA.). The anti-phospho Akt (Ser 473 #9271), anti-
phospho p70S6K (Ser424/Thr421 #9204), anti p70S6K (Thr 389, #9205), anti-Akt (#9272), 
anti-p70S6K (#9202), anti-phospho p44/p42 MAPK (Thr 202/Tyr 204 #9101S), anti-
p44/p42 MAPK (#9102), anti-phospho mTOR (Ser 2448 #2971), anti-phospho Foxo1 (Ser 
256 #9461) and anti-Foxo1 (#9462) antibodies were purchased from Cell Signaling 
(Beverly, MA). The anti insulin receptor beta-subunit antibodies for immunoprecipitation 
and for Western-blot (Ab3 and Ab4 respectively) were from Oncogene. For 
immunofluorescence FITC-conjugated sheep anti-mouse immunoglobulins and 
monoclonal anti-vimentin (cloneV9) antibody were from Roche Molecular Biochemicals 
(Mannheim, Germany). Immunofluorescence mounting medium was from Vector 
(Burlingame, CA). Insulin and IGF-I were purchased from Sigma and Preprotech (Rocky 
hill, NY) respectively. Wortmannin (#W1628), monoclonal anti-ß-actin clone AC-15 
(#A5441) and atractyloside (#6882) were from Sigma. PD98059 (#13000) and Rapamycin 
(#53210) were from Calbiochem (La Jolla, CA).  
7Generation of immortalized β-IRLoxP and β-IR -/- beta cell lines
         Fetal pancreata were harvested from IRLoxP mice at late gestation and digested with 
collagenase. Animals were handled in accordance with approved institutional procedures. 
Subsequently, 50-100 beta islets per pancreas were hand-picked under a dissection 
microscope and plated as previously described (14). At this stage of development, beta 
islets showed a differentiated phenotype yet maintained their proliferative capacity. Viral 
Bosc-23 packaging cells were transfected by the calcium phosphate method with 3 µg/6 
cm-dish of the puromycin-resistance retroviral vector pBabe containing attenuated SV40 
Large T antigen. Then, the beta islets growing on a fibroblasts monolayer were infected 
with the retroviral particles. After 72 h, islets were carefully hand-picked from the 
monolayer using a dissection microscope and replated. Beta cells obtained from these islets 
were expanded for one week in DMEM with 20%FBS in order to eliminate contaminating 
fibroblasts and subsequently, subjected to puromycin selection (1 µg/ml) for one week.  In 
addition, IRLoxP beta cells were subcloned twice to select them from other islet-derived 
cell types. Immortalized beta cells were established and grown in 10% FBS-DMEM. These 
cells maintained their cell-cell contact inhibition. For in vitro deletion of the insulin 
receptor, beta cells harboring a floxed allele of the insulin receptor (IRLoxP) were first 
placed at a subconfluent density. After 24 h, cells were infected with adenovirus encoding 
cre recombinase at a titer of 109 plaque-forming units. After 1 h, the viral supernatant was 
replaced with culture medium. Individual colonies were selected for IR recombination by 
PCR. Then, although these IR-deficient cells grew more slowly, they were cloned twice 
and re-subjected to viral infection to assure complete deletion of the insulin receptor.  
8Cell signaling
       For cell signaling experiments, both lines of beta cells, beta-IRLoxP and beta-IR-/-, 
were serum-starved for 16-20 hours and subsequently stimulated with insulin or glucose 
for 5 minutes and 15 minutes, respectively. Afterwards, cells were washed twice with PBS 
and lysed for total protein extraction according to standard procedure (14). This protocol 
was used in Figure 1.  
Immunoflourescence and confocal imaging  
       Cells were grown on glass coverslips until 80% confluence was reached. Then, cells 
were washed twice with PBS, fixed in methanol (-20ºC) for 2 min and processed for 
immunofluorescence. Primary antibodies (anti-insulin and anti-vimentin) were applied for 
1 h at 37ºC in PBS 1% BSA, followed by 4 x 5 min washes in PBS, a 45-min incubation 
with fluorescence conjugated antibodies (FITC-conjugated sheep anti-mouse and Cy3-
conjugated goat anti-rabbit), and four final washes of 5 min each in PBS. 
Immunoflourescence was examined in an MRC-1024 (Bio-Rad, Hempstead, UK) confocal 
microscope adapted to an inverted Nikon Eclipse TE 300 microscope.  
Reverse Transcription (RT)-PCR  
         Immortalized beta cells, primary islets and NIH3T3 fibroblasts (80-90% confluence) 
were serum-starved for 16-20 h and stimulated with glucose at 3 or 25 mM for 24 hours. 
Afterwards, cells were washed twice with PBS and lysed for total RNA extraction 
according to standard procedure (15). Total RNA was reverse transcribed into cDNA, as 
previously published (16).  
Immunoprecipitations and Western blot analysis
         Quiescent cells (20 h serum-starved) were treated with several doses of insulin and 
glucose and lysed as previously described (17). After protein content determination, 
western blot analysis was performed (17). 
9PI 3-kinase activity  
       PI 3-kinase activity was measured in the anti-Tyr(P) immunoprecipitates by in vitro 
phosphorylation of phosphatidylinositol as previously described (17). 
Cell proliferation  
        Cells were plated in 6 cm-multiwell plates and cultured in 10% FBS-DMEM until 40-
50 % of confluence was reached. Then, cells were serum-starved for a minimum of 4 hours 
in medium A (DMEM supplemented with 0,2 mM glucose, 0,5 % BSA) to assure cell 
survival. Beta-IRLoxP cells were pre-incubated with different inhibitors for 30 min and 
subsequently stimulated with 10 nM insulin for 2 h. The 2 h time-point was chosen as 
compromise between maximal proliferation response and cell survival. A shorter exposure 
did not reach maximal mitogenic response. A longer treatment with insulin, however, 
elicited increasingly cell death apoptotic rates. After 2 h, culture medium containing 
insulin was removed and replaced by medium A for up to 24 h. In parallel, beta-IR-/- cell 
were pre-incubated with inhibitors for 30 min and subsequently stimulated with 5 mM 
glucose for 24 hours. Then, both lines of beta cells were washed with PBS and stained with 
crystal violet (0,2 % in 2 % ethanol) for 10 min. Finally, plates were rinsed with water, 
dried and 1 % SDS was added. Absorbance of each plate was read at 560 nm. This 
protocol was used in Figures 2, 3, 4 and 5.  
Protein determination
       Protein determination was by the Bradford dye method (18), using the Bio-Rad 
reagent and BSA as the standard. 
RNA extraction and Northern blot analysis  
        Primary beta cells and MIN-6 cells were grown until confluence. Then, cells were 
serum-starved for 20 h and further incubated for 24 h in the presence of glucose (5 and 25 
10
mM). Then, total RNA was isolated as described (15) and submitted to Northern blot 
analysis (16). 
Results  
Characterization of immortalized beta cells  
      Our first goal was to characterize the phenotype of these new cell lines. Thus, we 
performed immunoflourescence with antibodies against insulin (a β-cell-specific marker) 
and vimentin (a marker for cells of mesenchymal origin). β-IRLoxP beta cells stained 
positive for insulin, indicating that these cells maintained beta cell phenotypic features. 
Conversely, the beta cell lines were negative for vimentin (Fig. 1A) in contrast to NIH3T3 
cells which served as a positive control for this antibody. The expression of insulin in β-
IRLoxP beta cells and isolated mouse islets was assessed by RT-PCR analysis. Clearly, 
these immortalized cells express insulin which could be induced by glucose in a 
concentration dependent-manner (Figure 1B). Previous data have demonstrated that 
glucose-stimulated insulin production is regulated by PDX-1 expression. Insulinoma MIN-
6 beta cells and β-IRLoxP beta cells were stimulated with glucose and PDX-1 expression 
was evaluated by Northern blot. An increase in PDX-1 expression was noted in both types 
of beta-cells in response to different glucose concentrations (Fig. 1C).  
        To assess the distinct contributions of glucose vs. insulin signaling, we generated ß-
cells lacking the insulin receptor (Fig. 1D). The deletion of the insulin receptor was further 
confirmed by analysis of insulin receptor phosphorylation. We observed an increase in IR 
β-chain tyrosine phosphorylation in a dose-dependent manner in β-IRLoxP beta cells. In 
contrast, insulin stimulation produced no detectable IR phosphorylation in Iß-IR-/- beta 
cells, as expected (Fig 1D).  
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Downstream PI 3-kinase-dependent and -independent signaling in β-IRLoxP and ß-IR-/- 
beta cells  
         The insulin signaling cascade begins when the activated IR phosphorylates tyrosine 
residues of insulin receptor substrate (IRS) docking proteins (19, 20). Then, 
phosphorylated IRSs bind proteins such as the p85 regulatory subunit of PI 3-kinase. 
Treatment of the β-IRLoxP beta-cell line with insulin or IGF-I for 2 h stimulated Tyr(P)-
associated PI 3-kinase activity. However, exposure to various concentrations of glucose for 
24 h had no effect on phophotyrosine-associated PI 3 kinase activity (Fig. 2A). These 
results exclude the possibility that glucose might activate insulin signaling pathways 
indirectly by triggering insulin secretion in fetal beta cells. In ß-IR-/- beta cells, 
phosphotyrosine-associated PI 3-kinase was not activated upon glucose stimulation. 
However, IGF-I stimulated phosphotyrosine-associated PI 3 kinase activity in a dose-
dependent manner in this cell line (Fig. 2A).  
       Beta-cells were serum-deprived for 4 h and then the β-IRLoxP line was stimulated 
with 10 nM insulin or IGF-I whereas  ß-IR-/- beta cells received 5 mM glucose or 10 nM 
IGF-I for 2 h (Fig 2 B). Downstream of PI 3 kinase, insulin and IGF-I stimulated Akt and 
also Foxo-1 phosphorylation in β-IRLoxP beta-cells. Neither Akt nor Foxo-1 were 
phosphorylated upon glucose stimulation in the IR-deficient cells. However, IGF-I induced 
both Akt and Foxo-1 phosphorylation, the level of phosphorylation reached was lower in  
IR-deficient cells as compared to β-IRLoxP beta-cells. Another substrate recruited by 
activated IR is SHC (21). Upon insulin stimulation, SHC proteins associate with Grb-2, 
resulting in the activation of the ras/MAPKs pathway. In βIR-LoxP beta cells, there was a 
dose-dependent increase in p44/p42 MAPK phosphorylation upon insulin or IGF-I 
stimulation.  
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Similarly, both glucose and IGF-I stimulated p44/p42 MAPKs phosphorylation in ß-IR-/- 
beta cells, the level of phosphorylation induced by IGF-I was lower in IR-deficient cells as 
compared to β-IRLoxP beta-cells. In fact, IR-deficient cells grew more slowly as compared 
to β-IRLoxP beta-cells. 
Differential regulation of mTOR /p70S6K signaling pathways in β-IRLoxP and β-IR-/- beta 
cells 
         A step further, stimulation with 10 nM insulin for 2 h induced mTOR and p70S6K   
phosphorylation in β-IRLoxP beta cells. Similarly, stimulation with 5 mM glucose for 24 h 
induced mTOR and p70S6K phosphorylation in ß-IR-/- beta cells (Figs. 3 and 4). Beta cell 
lines with or without insulin receptors were preincubated in the presence of 20 nM 
wortmannin (PI 3 kinase inhibitor), or 20 µM PD98059 (MEK1 inhibitor). Neither of these 
inhibitors produced a significant effect on insulin-induced mTOR phosphorylation in β-
IRLoxP beta cells. However, 20 nM wortmannin or 20 µM PD98059 inhibited 
phosphotyrosine-associated PI 3 kinase activity and p42/p44 MAPKs phosphorylation 
respectively, as expected (inset in Fig. 3). The combined treatment with wortmannin and 
PD98059 totally abolished the mTOR activation in response to 2 h stimulation with 10 nM 
insulin, as statistically quantified by densitometry (Fig. 3A). Wortmannin had only a 
statistically significant partial effect on insulin-induced p70S6K Thr421/Ser424 and 
Thr389 phosphorylation sites. PD98059 had also a statistically significant partial effect on 
insulin-induced p70S6K Thr421/Ser424 and Thr389 phosphorylation sites. The combined 
presence of wortmannin and PD98059 totally prevented the p70S6K full phosphorylation 
stimulated by insulin, as statistically quantified by densitometry (Fig. 4A). Finally, 20 nM 
rapamycin, mTOR kinase inhibitor, totally eliminated phosphorylation of Ser 2448 of 
mTOR as well as p70S6K full phosphorylation induced by insulin in β-IRLoxP beta cells, 
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its inhibitory effect was even below their corresponding basal levels (Figs. 3A and 4A 
respectively). These results suggest a convergence of PI 3 kinase and MEK-1 signaling on 
the mTOR/p70S6K pathway upon insulin stimulation in β-IRLoxP fetal pancreatic beta 
cells. 
        PD98059 inhibited phosphorylation of mTOR Ser 2448 which was induced by 
stimulation with 5 mM glucose for 24 h in β-IR-/- beta cells, as statiscally quantified (Fig. 
3B, left panel). In addition, wortmannin did not produce any significant direct effect on 
mTOR phosphorylation as densitometrically quantified (Fig. 3B, right panel). Moreover, 
we noted a differential effect of PD98059 on glucose-induced phosphorylation of p70S6K 
sites; whereas this inhibitor exerted no effect on Thr421/Ser424 phosphorylation sites, 
phosphorylation of Thr389 was completely blocked, as statistically quantified by 
densitometry (Fig 4B). Finally, treatment with rapamycin totally abolished the glucose-
mediated phosphorylation of mTOR Ser 2448 and p70S6K Thr421/Ser424 and Thr389 in 
β-IR-/- beta cells (Figs. 3B and 4B, respectively). In the presence of rapamycin plus 
PD98059, the effect on p70S6K Thr421/Ser424 phosphorylation site was even below its 
basal level (Fig. 4B). These results suggest that glucose may activate a MEK-
1/mTOR/p70S6K signaling pathway in insulin-receptor deficient beta cell lines.  
Mitogenic effects of insulin or glucose in immortalized beta cell lines
        Next, we studied the effects of insulin and glucose on ß-cell proliferation as 
determined by PCNA protein expression and ß-cell number. We observed that, during a 
24-h time-course, 10 nM insulin or 5 mM glucose increased PCNA protein expression in 
β-IRLoxP and βIR-/- cells, respectively (Fig. 5C and 5D respectively). In addition, there 
was a 20% increase in ß-cell number upon stimulation with either 10 nM insulin, 10 nM 
IGF-I, or 5 mM glucose stimulation in β-IRLoxP beta cells (Figs 5A). This is a remarkable 
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effect considering that none of the cell lines were synchronized. Glucose stimulated 
proliferation by 25% in βIR-/- beta cells; however, insulin had no mitogenic effect on this 
IR-deficient cell line, as would be expected. Interestingly, IGF-I increased proliferation by 
17% in β-cell line lacking insulin receptors (Fig. 5B). To assess which signaling pathways 
participate in the mitogenic effects of insulin and glucose, we tested the different inhibitors 
used in the experiments described above. Treatment with either 20 nM Wortmannin or 20 
µM PD98059 did not effect insulin-induced proliferation of the β-IRLoxP beta cell line. 
However, the combined addition of PD98059 and wortmannin completely blocked insulin-
induced β-cell mitogenesis (Fig. 5A). These results suggest that activation of both IRS-
dependent PI 3 kinase and MEK-1 pathways is required for beta-cell mitogenesis in 
response to insulin. Finally, 20 nM rapamycin abolished insulin-mediated mitogenesis in 
β-IRLoxP beta cells (Fig. 5A).  These results are consistent with those seen above in Figs 
3A and 4A, suggesting that signals from the PI 3 kinase and MEK-1 pathways converge on  
the mTOR/p70S6K pathway to mediate fetal beta-cell proliferation in response to insulin. 
         By contrast, in IR-deficient beta cells, the sole addition of PD98059 totally blunted 
glucose-stimulated mitogenesis. However, wortmannin had no effect on proliferation in 
this cell line (Fig. 5B) which was expected given that glucose did not activate PI 3 kinase 
signaling in IR-deficient cells. As observed in the IR-expressing beta cell line, rapamycin 
produced a total block of beta-cell mitogenesis in response to glucose, paralleling its 
inhibitory effect on mTOR/p70S6K signaling.  Finally, combined addition of PD98059 and 
rapamycin also inhibited mitogenesis of ß-IR-/- beta cells (Fig. 5B). These data are also 
consistent with data of Figs. 3B and 4B, suggesting that the MEK-1/mTOR/p70S6K 
pathway mediates fetal beta-cell proliferation in response to glucose.
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Discussion 
IGF-I is an important mitogen in many types of eukaryotic cells (22). In the developing 
and regenerating pancreas, IGF-I plays a major role in increasing the population of islet-
cells (6, 9). However, the IGF-I-induced mitogenic response appears to be glucose 
dependent, at least in vitro (10-12). Glucose-dependent activation of MAPK is required to 
maintain the balance between MAPKs/PI-3K/Akt in IGF-I-mediated β-cell proliferation 
(23). Additionally, glucose-dependent activation of p70S6K might also be crucial due to 
the mTOR-mediated degradation of IRS-2 during the mitogenic response to glucose and/or 
IGF-I (24).  Evidence from knockout mice has challenged classic notions about the roles of 
insulin and IGF-I in beta-cell physiology. Deletion of the IGF-IR specifically in beta-cells 
produces defective glucose-stimulated insulin secretion, but does not effect beta-cell mass 
(4). Beta-cell specific insulin receptor deficiency also results in an insulin secretion defect 
(3). However, a decrease in beta-cell mass and islet number occurs in most adult BIRKO 
mice as compared with controls (5). These results strongly suggest that insulin receptor 
signaling is essential for pancreatic beta-cell growth throughout development.     
         To address whether insulin indeed induces beta-cell proliferation, we have studied 
the insulin-induced mitogenic signaling in immortalized lines of mouse beta cells which do 
or do not express the insulin receptor. Upon insulin stimulation, the insulin receptor 
recruited docking proteins such as IRSs and also SHC in the β-IRLoxP cells. As expected, 
insulin activated the PI 3 kinase/Akt signaling pathway. However, 5 mM glucose failed to 
stimulate phophotyrosine-associated PI 3 kinase in our βIR-LoxP line of beta cells. These 
data rule out the possibility that low glucose might indirectly activate insulin signaling by 
stimulating insulin secretion in fetal beta cells. The MAPK pathway was also stimulated by 
insulin in these cells. Neither wortmannin nor PD98059 blocked the mitogenic response to 
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insulin. Consequently, neither IRS/PI 3 kinase signaling nor the IRS/ras/MAPKs pathway 
is sufficient to mediate the mitogenic activity of insulin in these beta cell lines. However, 
combined treatment with wortmannin and PD98059 completely abolished the insulin-
mediated mitogenic response. Thus, activation of both IRS-dependent signaling pathways 
is required for insulin-induced mitogenesis in these beta cells.  
Furthermore, combined treatment with PD98059 and wortmannin inhibited the 
insulin-stimulated phosphorylation of mTOR. Wortmannin alone partially blocked the 
insulin-induced phosphorylation of p70S6K at Thr421/Ser424 and Thr389 sites. In the 
same way, the MEK-1-inhibitor PD98059 had only a partial effect on insulin-induced 
phosphorylation of p70S6K at Thr421/Ser424 and Thr389 sites. Treatment with 
wortmannin plus PD98059 totally blocked p70S6K phosphorylation sites and mitogenesis 
as stimulated by insulin. Our results suggest that complete phosphorylation of p70S6K is 
required to achieve activation of p70S6K activity and the resulting mitogenesis, as recently 
reported (25). Moreover, these data suggest that the PI 3 kinase and MEK-1 pathways 
converge on mTOR/p70S6K signaling in response to insulin in our fetal pancreatic beta 
cell lines. In fact, this convergent signaling has been previously suggested to function in 
the EGF/insulin pathway, where active tuberin/hamartin heterocomplex playing a central 
role in the negative regulation of mTOR (26). Rapamycin totally abolished p70S6K 
phosphorylation sites and the phosphorylation of mTOR on serine 2448, thereby imparing 
insulin-induced mitogenesis in β-IRLoxP beta cells. These results are entirely consistent 
with recent evidence suggesting that p70S6K, but not Akt, directly leads to phosphorylation 
of mTOR on serine 2448 in cells (27,28). Thus, IRS-dependent complete activation of  
mTOR/p70S6K is necessary and sufficient to induce mitogenesis in response to insulin in 
fetal pancreatic beta cells. Moreover, these results demonstrate that insulin, acting 
independently of glucose signaling, induces mitogenesis in fetal beta cells. Therefore, our 
17
data provide further evidence that the insulin receptor is essential for the development of 
beta-cell mass in BIRKO mice (5).               
         Glucose itself stimulates mitogenesis in primary pancreatic beta cells, via a glucose- 
metabolism dependent mechanism (6, 8). Glucose metabolism increases intracellular 
cAMP and subsequently protein kinase-A (PKA) activity, PKC activity and cytosolic Ca2+
in beta-cells (29-31). Additionally, glucose induces IRS-1/IRS-2 phosphorylation and PI 3 
kinase activity with downstream activation of p70S6K (10, 11). Thus, the glucose-mediated 
increase of intracellular Ca2+ leads activation of PKA that acts downstream of Ras and 
upstream of MEK-1 to mediate p44/p42 MAPKs activation. Glucose also stimulates 
p70S6K via the mTOR-kinase which functions as an “ATP-sensor.” (32). However, these 
studies were performed in beta cell lines derived from insulinomas where insulin secretion 
is highly sensitive to glucose. Thus, it is possible that these reported effects of glucose on 
signaling and mitogenesis in insulinoma cell lines are the indirect result of abnormal 
insulin secretion.  
           To address if glucose itself directly triggers beta-cell mitogenesis, we have 
generated immortalized lines of fetal pancreatic beta cells lacking the insulin receptor. In 
these ß-IR-/- beta cells, glucose failed to stimulate phosphotyrosine-associated PI 3 kinase 
activity and its downstream effectors Akt and Foxo-1. These observations contradict 
previous data regarding IRS-mediated PI3-K activation in response to glucose in 
insulinoma-derived beta cells, suggesting that altered insulin secretion or other 
mechanisms must account for PI3-K activity in these cells. However, treatment with IGF-I 
activated phosphotyrosine-associated PI 3 kinase and its downstream effectors in ß-IR-/- 
beta cells. Thus, despite the lack of the insulin receptor, these cells maintain post-receptor 
signaling machinery.  
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Exposure to glucose alone increased p44/p42MAPKs phosphorylation in our IR-
deficient beta cell line. These data are consistent with those previously reported in INS-1 
beta-cells, where glucose activates phosphorylation of p44/p42 MAPs in the presence of a 
dominant negative form of ras (13). In addition, glucose evoked complete phosphorylation 
of mTOR and p70S6K via a PI3K-independent pathway in our studies. PD98059 inhibited 
glucose-mediated mTOR phosphorylation but exerted a site-specific effect on glucose-
induced phosphorylation of p70S6K. Whereas this inhibitor had no effect on 
Thr421/Ser424 phosphorylation sites, phosphorylation of Thr389 was completely 
eliminated. In parallel, PD98059 blocked glucose-induced mitogenesis in beta cells lacking 
insulin receptors. These results suggest the MEK-1/mTOR/p70S6K signaling pathway 
mediates mitogenic signaling in these cells, with the phosphorylation on Thr389 of p70S6K 
being required for glucose-induced mitogenesis. Furthermore, rapamycin inhibited 
phosphorylation of p70S6K as well as the ser2448 site of mTOR in β-IR-/- beta cells. 
These results also agree with recent evidence suggesting that p70S6K, but not Akt, directly 
leads to phosphorylation of mTOR on serine 2448 in cells (27,28). No rapamycin-
insensitive glucose-induced p70S6K phosphorylation sites were found in beta cells as 
previously described (25). Thus, rapamycin impaired beta-cell mitogenesis in response to 
glucose. Taken together, these data indicate that glucose-induced activation of MEK-
1/mTOR/p70S6K Thr389 signaling pathway is necessary and sufficient to induce 
mitogenesis in beta cells lacking insulin receptors. 
           In conclusion, our results demonstrate that the insulin receptor, independent of 
glucose signaling, plays an essential role in the regulation of mitogenesis in fetal pancreatic 
beta cell lines, requiring both the PI 3 kinase and MEK-1 pathways to fully activate 
mTOR/p70S6K. Moreover, our cell lines reveal that glucose induces beta-cell mitogenesis 
in the absence of the insulin receptor by activating signals which are not dependent on PI 3 
19
kinase, revealing that phosphorylation at Thr389 of p70S6K is necessary and sufficient to 
mediate mitogenesis in insulin-receptor deficient fetal beta cell lines (Fig.6).  
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Figure legends 
FIG. 1. Characterization of immortalized β-IRLoxP and ß-IR-/- beta cells. A. β-
IRLoxP and β-IR-/- beta cells and also NIH3T3 were cultured to confluence in the 
presence of 10% FBS-DMEM. Representative immunofluorescence detection of insulin 
and vimentin of growing immortalized fetal ß-IRLoxP beta cells and also vimentin in 
NIH3T3 cells is shown. B. ß-IRLoxP beta cells were cultured for 16-20 h in glucose-free 
DMEM and further stimulated with glucose at 3 or 25 mM for 24 hours. Representative 
RT-PCR for insulin mRNA expression of beta cells, mouse islets as a positive control and 
NIH3T3 cells as negative is shown. C. ß-IRLoxP and insulinoma MIN-6 beta cells were 
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cultured for 16-20 h in glucose-free DMEM and further stimulated with glucose 5 or 16 
mM for 24 hours. Total RNA (10 µg) was isolated, submitted to Northern blot analysis, 
and hybridized with Pdx-1 and 18S cDNAs. Densitometric study corresponding to three 
independent experiments is shown. D. β-IRLoxP and ß-IR-/- beta cells were lysed, and 600 
µg total protein was immunoprecipitated with the anti-IR ß-chain antibody, the resulting 
immune complexes were analyzed by Western blotting with the anti-IR ß-chain antibody 
respectively. Alternatively, ß-IRLoxP and ß-IR-/- beta cells were cultured for 16-20 h in 
glucose-free DMEM and further stimulated with insulin 1-10 nM for 5 min,  600 µg total 
protein immunoprecipitated with anti-IR antibodies and the resulting immune complexes 
were analyzed by Western blotting with the anti-P-Tyr antibody respectively. 
Representative autoradiograms out of three are shown.
FIG. 2. PI 3-kinase-dependent and -independent signaling in ß-IRLoxP and ß-IR-/- beta 
cells. ß-IRLoxP and ß-IR-/- beta cells were cultured to confluence in the presence of 10% 
FBS-DMEM. Then, cells were serum-starved in medium A (DMEM supplemented with 
0,2 mM glucose, 0,5 % BSA) A. ß-IRLoxP and ß-IR-/- beta cells, serum-deprived for 4 h, 
were cultured and stimulated with 10 nM insulin versus IGF-I for 2 h or with several 
concentrations of glucose for 24 h versus 10 nM IGF-I for 2 h, respectively. At the end of 
the culture time, cells were lysed and 600 µg total protein immunoprecipitated with anti-
tyrosine phosphate antibodies and the resulting immune complexes were washed and 
immediately used for an in vitro PI 3 kinase assay. The conversion of PI to PIP in the 
presence of [ 32-P]ATP was analyzed by thin-layer chromatography. Representative 
autoradiograms out of three are shown. B. ß-IRLoxP and ß-IR-/- beta cells, serum-deprived 
for 4 h, were cultured and stimulated with 10 nM insulin versus IGF-I for 2 h or with 
several concentrations of glucose for 24 h versus 10 nM IGF-I for 2 h respectively. Cells 
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were lysed, and total protein (50 µg) was submitted to SDS-PAGE and analyzed by 
immunoblotting with the corresponding antibodies against, phospho-Akt (Ser 473), total 
Akt, phospho-Foxo1 (Ser 256), total Foxo, phospho-p44/p42 MAPKs and total p44/p42 
MAPKs. Representative autoradiogram out of three is shown.
FIG. 3.  Differential regulation of mTOR signaling pathway in ß-IRLoxP and ß-IR-/- 
beta cells. ). β-IRLoxP and βIR-/- beta cells were grown to confluence in the presence of 
10% FBS-DMEM. Then, cells were serum-starved in medium A (DMEM supplemented 
with 0,2 mM glucose, 0,5 % BSA). A. ß-IRLoxP beta cells, serum starved for 4 h, were 
preincubated with 20 µM PD98059, or 20 nM wortmannin, or PD98059 plus wortmannin, 
or 20 nM rapamycin, for 30 minutes. Then, were stimulated with 10 nM insulin for 2 h.
Total protein (50-120 µg) was submitted to SDS-PAGE and analyzed by immunoblotting 
with the corresponding antibodies against, phospho-mTOR (Ser 2448) and ß-actin. B. ß-
IR-/- beta cells, serum-starved for 4 h, were preincubated with 20 µM PD98059, or 20 nM 
rapamycin, or PD98059 plus rapamycin, for 30 minutes (upper left panel). Then, cells were 
stimulated with 5 mM glucose for 24 h. Total protein (50-120 µg) was submitted to SDS-
PAGE and analyzed by immunoblotting with the corresponding antibodies against, 
phospho-mTOR (Ser 2448) and ß-actin. A representative experiment out of four is shown. 
Densitometric analysis of four independent experiments is also shown. Results are means ± 
S.E.M. #p<0,05 PD+Wort+Insulin or rapamycin+insulin vs insulin (panel A) and PD+ 
glucose, rapamycin+glucose and PD+rapamycin+glucose vs glucose (panel B). 
Alternatively, cells were preincubated with 20 nM wortmannin and further stimulated with 
or without 5 mM glucose for 24 h (upper right panel). A representative experiment out of 
three is shown. Fold-increase values referred to their corresponding basal values from 
densitometric analysis of three independent experiments are represented above lanes. Inset 
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on wortmannin or PD98059 control effect on PI 3-kinase activity or p42/p44 MAPKs 
phosphorylation respectively is also shown.   
FIG. 4.  Differential regulation of p70S6K signaling pathway in ß-IRLoxP and ß-IR-/- 
beta cells. β-IRLoxP and βIR-/- beta cells were grown to confluence in the presence of 
10% FBS-DMEM. Then, β-IRLoxP and βIR-/- beta cells were serum-starved in medium A 
(DMEM supplemented with 0,2 mM glucose, 0,5 % BSA). A. ß-IRLoxP beta cells, serum 
starved for 4 h, were preincubated with 20 µM PD98059, or 20 nM wortmannin, or 
PD98059 plus wortmannin, or 20 nM rapamycin, for 30 minutes. Then, were stimulated 
with 10 nM insulin for 2 h. Total protein (50-120 µg) was submitted to SDS-PAGE and 
analyzed by immunoblotting with the corresponding antibodies against, phospho-p70S6K 
(Thr 421/Ser 424), phospho-p70S6K (Thr 389) and ß-actin. B. ß-IR-/- beta-cells, serum-
starved for 4 h, were preincubated with 20 µM PD98059, or 20 nM rapamycin, or 
PD98059 plus rapamycin, for 30 minutes. Then, cells were stimulated with 5 mM glucose 
for 24 h. Total protein (50-120 µg) was submitted to SDS-PAGE and analyzed by 
immunoblotting with the corresponding antibodies against, phospho-p70S6K (Thr 421/Ser 
424), phospho-p70S6K (Thr 389) and ß-actin. A representative experiment out of four is 
shown. Densitometric analysis of four independent experiments is also shown. Results are 
means ± S.E.M. #p<0,05 PD+insulin, Wort+insulin, PD+Wort+insulin or 
rapamycin+insulin vs insulin 5 min (panel A) and PD+glucose, rapamycin+glucose and 
PD+rapamycin+glucose vs glucose 5 mM (panel B).
FIG. 5.  Beta-cell proliferation in ß-IRLoxP and ß-IR-/- beta cells β-IRLoxP and βIR-/- 
beta cells were grown to 50% confluence in the presence of 10% FBS-DMEM. Then, β-
IRLoxP and βIR-/- beta cells were serum-starved in medium A (free-glucose DMEM 
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supplemented with 0,2 mM glucose, 0,5 % BSA). ß-IRLoxP beta-cells, serum-starved for 4 
h, were preincubated with 20 µM PD98059, or 20 nM wortmannin, or PD98059 plus 
wortmannin, or 20 nM rapamycin for 30 minutes and further stimulated with 10 nM insulin 
for 2 h. Also cells were stimulated with 10 nM IGF-I for 2 h or 5 mM glucose for 24 h as 
controls. Then, culture medium was withdrawn and ß-IRLoxP beta cells were stained with 
violet crystal after 24 hours. (panel A).  ß-IRLoxP beta cells, serum-starved for 4 h, were 
stimulated with 10 nM insulin for 2 h, in a time-dependent manner. Then, PCNA protein 
expression was measured by western-blot (panel C). ß-IR-/- beta cells, serum starved for 4 
h, were preincubated with 20 µM PD98059, or 20 nM rapamycin, or PD98059 plus 
rapamycin, or 20 nM wortmannin, for 30 minutes and further stimulated with 5 mM 
glucose for 24 h. Also they were stimulated with 10 nM insulin or IGF-I for 2 h as 
controls. Then, culture medium was withdrawn and ß-IR-/- beta cells cells were stained 
with violet crystal. (panel B). ß-IRLoxP beta cells, serum-starved for 4 h, were stimulated 
with 5 mM glucose for 24 h, in a time-dependent manner. Then, PCNA protein expression 
was measured by western-blot (panel D). Results are means ± SEM of six independent 
experiments. *p<0,05 insulin, or glucose, or IGF-I vs control (panels A); glucose, or IGF-I 
versus control (panel B), ·#p<0,05 PD+Wort or rapamycin vs insulin; PD, rapamycin or 
PD+rapamycin vs glucose (panels A and B respectively). 
FIG. 6. Converging mTOR/p706K signaling pathway in beta-cell mitogenesis. Insulin 
independently of glucose signals through IRS-dependent PI 3 kinase/Akt and MEK-1 
pathways in ß-IRLoxP beta cells. However, glucose, in a PI 3 kinase-independent manner, 
induces MEK-1 in β-IR-/- beta cells. Both signalings converge on mTOR/ p70S6K 
pathway to mediate fetal beta-cell proliferation.     
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